Role of the serotonergic nervous system in anxiety disorders and the anxiolytic mechanism of selective serotonin reuptake inhibitors

Japanese Journal of Neuropsychopharmacology

Volumn 26, Issue 5-6, 2006, Pages 193-198

  Yamauchi, Miki ^a   Hiraoka, Shuichi ^a   Imanishi, Taiichiro ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

Anxiety disorder; m chlorophenylpiperazine; Selective serotonin reuptake inhibitor; Serotonin receptor

Indexed keywords

FLUVOXAMINE; PAROXETINE; SEROTONIN 4 RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; BRAIN REGION; HUMAN; JAPAN; LONG TERM CARE; RECEPTOR DOWN REGULATION; SEROTONINERGIC SYSTEM; SHORT SURVEY; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY DISORDERS; FLUVOXAMINE; HUMANS; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 33846091666     PISSN: 13402544     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (50)

1. 2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol, 8: 391-401.
2. Alvarez, J. C., Gluck, N., Arnulf, L, Quintin, P., Leboyer, M., Pecquery, R., Launay, J. M., Perez-Diaz, F. and Spreux-Varoquaux, O. (1999) Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: Effects of clomipramine and fluoxetine. Clin Pharmacol Ther, 66: 617-624.
3. Asakura, S., Tajima, O. and Koyama, T. (2006) Fluvoxamine treatment of generalized social anxiety disorder in Japan: A randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol, in press.
4. 1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol, 4: 399-408.
5. Chambers, C. D., Hernandez-Diaz, S., Van Marter, L. J., Werler, M. M., Louik, C., Jones, K. L. and Mitchell, A. A. (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med, 354: 579-587.
6. 1A receptors in rat brain. Neuropharmacology, 44: 93-101.
7. 2B receptors. Behav Pharmacol, 12: 613-620.
8. 2A receptor function by long-term imipramine treatment in endogenous depression. Hum Psychopharmacol, 19: 251-258.
9. 2A receptors by agonists and antagonists. Brain Res Bull, 56: 441-451.
10. Hamrin, V. and Scahill, L. (2005) Selective serotonin reuptake inhibitors for children and adolescents with major depression: Current controversies and recommendations. Issues Ment Health Nurs, 26: 433-450.
11. 2A receptor mediation of the HPA axis. Neuropharmacology, 42: 162-169.
12. Hollander, E., DeCaria, C., Gully, R., Nitescu, A., Suckow, R. F., German, J. M., Klein, D. F. and Liebowitz, M. R. (1991) Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res, 36: 1-17.
13. Hollander, E., Kwon, J., Weiller, F., Cohen, L., Stein, D. J., DeCaria, C., Liebowitz, M. and Simeon, D. (1998) Serotonergic function in social phobia: Comparison to normal control and obsessive-compulsive disorder subjects. Psychiatry Res, 79: 213-217.
14. Japanese source
15. Japanese source
16. Kahn, R. S. and Wetzler, S. (1991) m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry, 30: 1139-1166.
17. Kahn, R. S., Wetzler, S., van Praag, H. M., Asnis, G. M. and Strauman, T. (1988a) Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res, 25: 101-104.
18. Kahn, R. S., Asnis, G. M., Wetzler, S. and van Praag, H. M. (1988b) Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology (Berl), 96: 360-364.
19. (Jpn Pharmacol Ther), 32:577-591.
20. Kamijima, K., Kuboki, T., Kumano, H., Burt, T., Cohen, G., Arano, I. and Hamasaki, T. (2005) A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol, 20: 265-273.
21. Kennedy, A. J., Gibson, E. L., O'Connell, M. T. and Curzon, G. (1993) Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacology (Berl), 113: 262-268.
22. 2C/2B receptor function. Neuropharmacology, 33: 1581-1588.
23. 2C receptor antagonist. Neuropharmacology, 36: 609-620.
24. 1A receptors. J Pharmacol Exp Ther, 282: 1581-1590.
25. Li, X. B., Inoue, T., Hashimoto, S. and Koyama, T. (2001) Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear. Eur J Pharmacol, 425: 43-50.
26. Maj, J. and Moryl, E. (1992) Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm Gen Sect, 88: 143-156.
27. 2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav, 71: 615-625.
28. Masand, P. S. and Gupta, S. (1999) Selective serotonin-reuptake inhibitors: An update. Harv Rev Psychiatry, 7: 69-84.
29. 2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies. Therapie, 60: 441-460.
30. Japanese source
31. Pandey, G. N. (1997) Altered serotonin function in suicide. Evidence from platelet and neuroendocrine studies. Ann NY Acad Sci, 836: 182-200.
32. Pigott, T. A., Zohar, J., Hill, J. L., Bernstein, S. E., Grover, G. N., Zohar-Kadouch, R. C. and Murphy, D. L. (1991) Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry, 29: 418-426.
33. Quested, D. J., Sargent, P. A. and Cowen, P. J. (1997) SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology (Berl), 133: 305-308.
34. 1A receptors: Reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther, 288: 98-106.
35. Rauch, S. L., Shin, L. M. and Wright, C. I. (2003) Neuroimaging studies of amygdala function in anxiety disorders. Ann NY Acad Sci, 985: 389-410.
36. Rosen, J. B. (2004) The neurobiology of conditioned and unconditioned fear: A neurobehavioral system analysis of the amygdala. Behav Cogn Neurosci Rev, 3: 23-41.
37. Sanders-Bush, E., Breeding, M., Knoth, K. and Tsutsumi, M. (1989) Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system. Psychopharmacology (Berl), 99: 64-69.
38. Stahl, S. M. (2000) Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Second Edition, Cambridge University Press
39. Japanese source
40. Japanese source
41. Japanese source
42. Pharma Medica, 20: 155-121
43. Japanese source
44. (Jpn Pharmacol Ther), 28 (Suppl 1): 271-294
45. (Jpn Pharmacol Ther), 28 (Suppl 1): 295-314
46. U. S. Food and Drug Administration (2005). FDA Advising of Risk of Birth Defects with Paxil: Agency Requiring Updated Product Labeling. Retrieved December 8, 2005, from http://www.fda.gov/ bbs/topics/NEWS.htm
47. 2C receptor inverse agonist with improved anxiolytic profile: Lack of tolerance and withdrawal anxiety. Neuropharmacology, 41: 186-199.
48. 2C receptor-mediated hypolocomotion in rats. Pharmacol Biochem Behav, 78: 683-689.
49. 2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res, 1067: 164-169.
50. Zohar, J., Mueller, E. A., Insel, T. R., Zohar-Kadouch, R. C. and Murphy, D. L. (1987) Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry, 44: 946-951.